Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:bupropion
gptkb:naltrexone |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
A08AA62
|
| gptkbp:contains |
8 mg naltrexone
90 mg bupropion |
| gptkbp:contraindication |
uncontrolled hypertension
chronic opioid use seizure disorder |
| gptkbp:form |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mysimba
|
| gptkbp:indication |
weight management
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Orexigen_Therapeutics
|
| gptkbp:mechanismOfAction |
appetite suppression
modulation of reward pathways |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness headache insomnia |
| gptkbp:usedFor |
obesity
overweight with comorbidities |
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:bfsLayer |
5
|